GIOSTAR Launches Stem Cell Therapy Center in Cancun Riviera

PLAYA DEL CARMEN, Mexico, Jan. 14, 2020 /PRNewswire/ — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the pioneer in stem cell-based technologies, is proud to announce the launch of a new stem cell therapy center in the Cancun Riviera, Mexico. With this announcement, GIOSTAR further bolsters its leadership in the global medical tourism market, which is projected to grow at a compound annual growth rate (CAGR) of 16.1% for the next 5 years. The Cancun Riviera center highlights GIOSTAR’s continued expansion of its presence in Mexico, which also includes facilities in Los Algodones and Guadalajara.

Stem cells are unspecialized unique body cells that may help patients better manage symptoms of multiple sclerosis, arthritis, and other degenerative diseases. In addition to its clinics such as GIOSTAR Cancun Riviera, the GIOSTAR management team collaborates closely with leading government agencies to create stem cell therapy and research programs in Japan, China, Costa Rica, and Thailand. “This center is a testament to the commitment from the thousands of patients GIOSTAR has treated throughout the world,” noted GIOSTAR CEO and Co-Founder Deven Patel. “It’s only because of their trust in our capabilities that we’ve been able to grow our infrastructure.”

GIOSTAR Cancun Riviera offers several key benefits, including:

• Great vacation destination: Cancun has long been regarded as one of the world’s most attractive vacation destinations, with beautiful beaches, vibrant nightlife, and ample shopping opportunities.
• Easy access: the GIOSTAR facility is located near Mexico’s second largest airport (Cancun International Airport), making it accessible via direct flights from numerous cities throughout the world.
• Therapies backed by decades of research: GIOSTAR Cancun Riviera’s highly skilled professionals are trained extensively in the lab techniques and protocols developed by GIOSTAR Chairman and Co-Founder, Dr. Anand Srivastava.

Due to these advantages, Mr. Patel remarked that “this center helps GIOSTAR to continue executing on our mission to make the most advanced, elite, and expensive science available to the masses.”

As with the GIOSTAR center in Los Algodones, Mexico, GIOSTAR Cancun Riviera is integrated with other facilities such as the Sani Dental Group dental clinic. This provides patients the opportunity to receive comprehensive health care while taking advantage of the amenities offered in the surrounding Playa del Carmen area.

Additionally, the colors of the walls and furniture, the wood used in the fixtures, and other aesthetic elements of the center are closely aligned with those of the Mayan Riviera. “We wanted the center to look as authentic (yet modern) as possible,” noted GIOSTAR Mexico Chief Operating Officer Alejandro Gutiérrez. “The Cancun Riviera facility reflects Dr. Srivastava’s belief that stem cell therapy patients will maximize their success rate when they’re in a relaxed state of mind.”

Upcoming plans for 2020 include an “official inauguration event” in February, along with tentative plans to open an additional center in Mexico.

About GIOSTAR

GIOSTAR is the pioneer and established leader in the field of regenerative medicine. Under Dr. Anand Srivastava’s leadership, the San Diego-based Institute has a tradition of groundbreaking research in the field of stem cell science spanning more than two decades.

Source : https://www.prnewswire.com/news-releases/giostar-launches-stem-cell-therapy-center-in-cancun-riviera-300986482.html

GIOSTAR Signed MOU To Develop Advanced Stem Cell Center at Calicut University Kerala

GIOSTAR Chairman and Co-founder Dr. Anand Srivastava and Vice Chancellor, Dr. Mohammed Basheer of Calicut University,  Kerala Signed an Agreement to Develop Advanced Stem Cell Center under the direction of GIOSTAR

GIOSTAR Diabetes Type-2 Pre IND Clinical Trial – US FDA

GIOSTAR Diabetes Type-2 Pre IND Clinical Trial – US FDA

GIOSTAR – Diabetes Type-2 Clinical Trial with US-FDA News in “The Introducer”

GIOSTAR Engaged with USA FDA to Carry 0ut Stem Cells-Based Clinical Trial for Diabetes Type 2

Diabetes is increasing at a rampant rate all around the globe which is affecting developed countries more severely than developing ones. In the USA itself, almost 10% of the population has been living with diagnosed or undiagnosed diabetes. Since such a big section of the population is affected by diabetes, the cost of taking care of the individuals is also increasing. According to an assessment by the Diabetes Association of America, the cost of taking care of diabetics had added up to $327 billion in 2017. Out of which $237 billion was direct medical cost and remaining because of reduced productivity. Type II diabetes, which is caused by loss of insulin sensitivity is seen more commonly in the older population. However, with increasing easy and unimpeded availability of high-calorie foods and decreasing factors necessitating physical work, it is showing up in the younger population significantly. About 193,000 Americans under the age of 20 years are estimated to have diagnosed diabetes.

Though a number of medications are already in clinical use, none of them grant a long-term cure and all of them have some or other undesired side effects. To circumvent all these concerns another alternative way of handling the problem was needed for a long time. Discovery of stem cells and related extensive research has offered a ray of hope to manage the problem efficiently with a sound possibility of a permanent cure. Stem cells, depending on the source of their origin or due to post-isolation manipulations, are classified as embryonic or adult or induced.

Keeping different facts in a view, GIOSTAR Chairman, Dr. Anand Srivastava, started his research to differentiate stem cells into the insulin-secreting cells, which may be used for therapeutic purposes. Therefore, GIOSTAR is in the process of USA-FDA approval for a clinical trial to develop a stem cell-based treatment for Diabetes type 2. DR. ANAND SRIVASTAVA, M.S., PH.D. – CHAIRMAN, CO-FOUNDER, AND CHIEF SCIENTIFIC OFFICER

Mesenchymal stem cells (MSCs), isolated from visceral fatty tissues of adults, are known to promote the regeneration of pancreatic islet beta cells, protect them from apoptosis, and ameliorate insulin resistance in peripheral tissues by providing a supportive niche microenvironment driven by the secretion of paracrine factors or the deposition of the extracellular matrix. In general, implantation of MSCs can alleviate T2D by a number of mechanisms that include reducing systemic oxidative stress, a factor responsible for causing the death of insulin-producing cells and at the same time, contributing to insulin resistance too. Also, these cells, after being exposed to pro-inflammatory cytokines like IFN-g, become a source of anti-inflammatory cytokines. These cells, if implanted directly in the pancreas, due to their multipotential ability to differentiate in diverse types of cells of their immediate vicinity, can produce new insulin-producing cells. To promote the chances of their differentiation into insulin-producing cells, their preprogramming has been tried. Also, intravenous infusion of stem cells has been shown to regenerate beta cells of pancreatic islets and promote insulin sensitivity by decreasing systemic inflammation, the root cause of insulin resistance.

Encouraging findings in cases of diabetes treatments with stem cell therapies have led many clinicians to try implantation or infusion or both in the clinics. In more than 150 trials at different stages listed on NIH’s webpage implantation or infusion of MSCs have shown promising results up to several months of follow up. A couple of clinical parameters like H1Ac and needed insulin to manage blood glucose decreased after the MSC-treatments, which was also accompanied by increased insulin sensitivity.

Stem cell therapy may have some undesirable effects, though the incidences are few and far between. Even those undesired effects like mild to moderate fever or nausea or headache, which happen after stem cell transplantation, are very mild and are easily manageable.

In conclusion, GIOSTAR Chairman Dr. Anand Srivastava stated that stem cell therapy may offer a long-lasting therapeutic alternative for treating T2D. At the same time, it has to be kept in mind that it is not a permanent cure yet. T2D is a metabolic syndrome manifesting after a long duration of an unhealthy lifestyle that needs to be addressed in order to lead a healthy life. Compared to all other available therapies, stem cell therapy may offer a lot longer drug-free periods for individuals to develop a healthy lifestyle in order to fend off the re-occurrence of the disease.

Deven’s Networking Interest:  Hospitals and clinics interested in partnering for clinical trials.

Linkedin:  https://www.linkedin.com/in/deven-patel-38991455/

Website:  http://giostar.com/

Source : https://www.theintroducermagazine.com/league-members-innovating-for-diabetics/

Little Da Vincis: Interview with Dr. Anand Srivastava

Little Da Vincis: Interview with Dr. Anand Srivastava

DR. ANAND SRIVASTAVA INTERVIEW PODCAST ON AMAZON ALEXA

DR. ANAND SRIVASTAVA INTERVIEW PODCAST ON AMAZON ALEXA